Key facts
- Notable investors include Lerer Hippeau, Habitat Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Elm Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Elm Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elm Biosciences
Developer of clinical skincare products designed to address the signs of aging. The company, through a five-year collaboration with dermatologists, has developed a dual-pathway system that features both a topical serum and a daily skin supplement, targeting internal and external factors such as inflammation, oxidative stress, dehydration, and UV damage, thereby enabling consumers to support their skin's health and longevity.
- Sector
- Consumer Products and Services (B2C)
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- elmbiosciences.com/
- Ownership
- Privately Held (backing)
Elm Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elm Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elm Biosciences in its N-PORT filings yet. We sweep new filings monthly.